Erlonat (Erlotinib) 150 mg

Indicated for the treatment of:

• Non-Small Cell Lung Cancer (NSCLC): For patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Also used as maintenance or second-line therapy.
• Pancreatic Cancer: Combined with Gemcitabine for locally advanced, unresectable, or metastatic disease.

Strength: 150 mg tablet.

Standard Dose: 150 mg once daily.

⚠️ CRITICAL INSTRUCTIONS:

• 🚫 Take on an EMPTY STOMACH: At least 1 hour before or 2 hours after meals. Food increases drug levels to toxic limits.
• 🚬 No Smoking: Smoking induces enzymes that metabolize the drug too fast, reducing efficacy by ~50%.
• 💊 Drug Interactions: Avoid Proton Pump Inhibitors (like Omeprazole).

• Severe hepatic impairment.
• Pregnancy (Category D) and breastfeeding.
• Active peptic ulcer disease.
• Severe hypersensitivity to Erlotinib.